Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...
Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
From a virus's point of view, invading our cells is a matter of survival. The virus makes a living by highjacking cellular processes to produce more of the proteins that make it up. From our point of ...
U.K. scientists have used mass spectrometry to look in detail at how adeno-associated viruses (AAVs) release their genetic cargo when infecting host cells. The team, from the University of Leeds, ...
– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback